Cencora Inc (COR) Stock Forecast & Price Target

Cencora is well positioned by its dominant share in a highly concentrated U.S. wholesale market, its expanded international footprint through Alliance Healthcare in 2021, and its growing mix of higher-margin specialty, commercialization, and logistics services. The commentary points to stable end markets, continued specialty volume strength, and more than 100 oncology molecules expected through 2030, all of which should support durable growth in the categories that drive core distribution EBIT. Management also highlighted $100Bn in specialty distribution revenue in FY27+, MSO assets contributing about 10% of enterprise EBIT in FY26, and ongoing digital investments that should improve the cost structure over time.

Cencora is facing a weaker fundamental setup because management guided Pharma segment EBIT growth of just 2-4%, below the long-term range, while FX pressure and Walgreens-related non-prime volume loss suggest limited near-term operating leverage. Its core growth engine is exposed to prescription drug volume and pricing deceleration, and potential IRA-driven reimbursement pressure in 2028 could compress wholesaler economics just as specialty growth slows and customer concentration remains high. The Alliance Healthcare expansion adds Europe exposure, but centralized healthcare systems, government-controlled pricing, and volatile trial activity may dilute demand, while working-capital intensity, competitive animal health dynamics, and ongoing opioid litigation add further downside risk.